Stability of highly purified human paraoxonase (PON1): Association with human phosphate binding protein (HPBP) is essential for preserving its active conformation(s)

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1774, Issue 7, 2007, Pages 874-883

  Rochu, Daniel ^a,b   Renault, Frédérique ^a   Cléry Barraud, Cécile ^a   Chabrière, Eric ^c   Masson, Patrick ^a  

^a CENTRE DE RECHERCHES   (France)

^b BUNDESWEHR INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (Germany)

^c Nancy University CNRS   (France)

Author keywords

Biopharmaceutical; Catalytic scavenger; Enzyme therapy; Nerve agent; Paraoxonase; Protein stability

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HYBRID PROTEIN; ORGANOPHOSPHATE; PHOSPHATE BINDING PROTEIN; RECOMBINANT PROTEIN;

ARTICLE; ENZYME PURIFICATION; HUMAN; INTOXICATION; MOLECULAR SIZE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; STORAGE; THERMOSTABILITY; VASCULAR DISEASE;

ARYLDIALKYLPHOSPHATASE; CALORIMETRY, DIFFERENTIAL SCANNING; CATALYSIS; CHROMATOGRAPHY; DURAPATITE; ELECTROPHORESIS, CAPILLARY; ESCHERICHIA COLI; HEAT; HUMANS; PHOSPHATE-BINDING PROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEINS; RECOMBINANT PROTEINS; TEMPERATURE;

EID: 34250882686     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2007.05.001     Document Type: Article

References (42)

1. La Du B.N., Aviram M., Billecke S., Navab M., Primo-Parmo S., Sorensen R.C., and Standiford T.J. On the physiological role(s) of the paraoxonases. Chem.-Biol. Interact. 119-120 (1999) 379-388
2. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275 (2000) 3957-3962
3. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowala J., and Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14 (1996) 334-336
4. Khersonsky O., and Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44 (2005) 6371-6382
5. Aharoni A., Gaidukov L., Yagur S., Toker L., Silman I., and Tawfik D.S. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 482-487
6. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
7. Rochu D., Chabrière E., and Masson P. Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 233 (2007) 47-59
8. James R.W., and Deakin S.P. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radical Biol. Med. 37 (2004) 1986-1994
9. Gaidukov L., and Tawfik D.S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDLwith apoA-I. Biochemistry 44 (2005) 11843-11854
10. Fokine A., Morales R., Contreras-Martel C., Carpentier P., Renault F., Rochu D., and Chabrière E. Direct phasing at low resolution of a protein co-purified with human paraoxonase (PON1). Acta Cryst. D59 (2003) 2083-2087
11. Contreras-Martel C., Carpentier P., Morales R., Renault F., Chesne-Seck M.L., Rochu D., and Chabrière E. Crystallization of the human phosphate binding protein. Acta Cryst. F62 (2006) 67-69
12. Morales R., Berna A., Carpentier P., Contreras-Martel C., Renault F., Nicodeme M., Chesne-Seck M.L., Bernier F., Schaeffer C., Diemer H., Van-Dorsselaer A., Fontecilla-Camps J.C., Masson P., Rochu D., and Chabrière E. Serendipitous discovery and X-ray structure of a human phosphate binding apolipoprotein. Structure 14 (2006) 601-609
13. Rochu D., Chabrière E., Renault F., Elias M., Cléry-Barraud C., and Masson P. Functional states, storage and thermal stability of human paraoxonase: drawbacks, advantages and potentialities. Toxicology 233 (2007) 226
14. Teiber J.F., Draganov D.I., and La Du B.N. Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH. J. Lipid Res. 45 (2004) 2260-2268
15. Connelly P.W., Draganov D., and Maguire G.F. Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxinitrite. Free Radical Biol. Med. 38 (2005) 164-174
16. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., and La Du B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46 (2005) 1239-1247
17. James R.W., Kalix B., Bioletto S., and Brulhart-Meynet M.-C. Paraoxonase-1 promoter polymorphism C-107T and serum apolipoprotein AI interact to modulate serum paraoxonase-1 status. Pharmacogenet. Genomics 15 (2005) 441-446
18. Josse D., Xie W., Renault F., Rochu D., Schopfer L.M., Masson P., and Lockridge O. Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities. Biochemistry 38 (1999) 2816-2825
19. Gan K.N., Smolen A., Eckerson H.W., and La Du B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19 (1991) 100-106
20. Renault F., Chabrière E., Andrieu J.P., Dublet B., Masson P., and Rochu D. Tandem purification of two HDL-associated partner proteins in human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP) using hydroxyapatite chromatography. J. Chromatogr., B 836 (2006) 15-21
21. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
22. Furlong C.E., Richter R.J., Chapline C., and Crabb J.W. Purification of rabbit and human serum paraoxonase. Biochemistry 30 (1991) 10133-10140
23. Rochu D., Ducret G., and Masson P. Measuring conformational stability of proteins using an optimized temperature-controlled capillary electrophoresis approach. J. Chromatogr., A 838 (1999) 157-165
24. Hilser V.J., Worosila G.D., and Freire E. Analysis of thermally induced protein folding/unfolding transitions using free solution capillary electrophoresis. Anal. Biochem. 208 (1993) 125-131
25. Rochu D., and Masson P. Multiple advantages of capillary zone electrophoresis for exploring protein conformational stability. Electrophoresis 23 (2002) 189-202
26. Smolen A., Eckerson H.W., Gan K.N., Hailat N., and La Du B.N. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab. Dispos. 19 (1991) 107-112
27. Josse D., Ebel C., Stoebel D., Fontaine A., Borges F., Echalier A., Baud D., Renault F., le Maire M., Chabrieres E., and Masson P. Oligomeric states of the detergent-solubilized human serum paraoxonase (PON1). J. Biol. Chem. 277 (2002) 33386-33397
28. Kuo C.-L., and La Du B.N. Comparison of purified human and rabbit serum paraoxonases. Drug Metab. Dispos. 23 (1995) 935-944
29. Lotti M., Moretto A., and Traverso R. Serum 'A' esterases and organophosphates toxicity in man. In: Reiner E., Aldridge W.N., and Hoskin F.C.G. (Eds). Enzymes hydrolyzing organophosphorus compounds (1989), Ellis Horwood, New York 192-201
30. Nguyen S.D., and Sok E.-E. Beneficial effect of oleoylated lipids on paraoxonase1: protection against oxidative inactivation and stabilization. Biochem. J. 375 (2003) 275-285
31. Marton A., and Kalow W. Studies of aromatic esterases and cholinesterase of human serum. Can. J. Biochem. Physiol. 37 (1959) 1367-1373
32. Erdos E.G., Debay C.R., and Westerman M.P. Arylesterase in blood: effects of calcium and inhibitors. Biochem. Pharmacol. 5 (1960) 173-186
33. Gil F., Gonzalvo M.C., Hernández A.F., Villanueva E., and Pla A. Differences in the kinetic properties, effect of calcium and sensitivity to inhibitors of paraoxon hydrolase activity in rat plasma and microsomal fraction from rat liver. Biochem. Pharmacol. 48 (1994) 1559-1568
34. Gil F., Gonzalvo M.C., Hernández A.F., and Villanueva E. Partial purification of paraoxonase from rat liver. Chem.-Biol. Interact. 87 (1993) 69-75
35. Rodrigo L., Gil F., Hernández A.F., Marina A., Vazquez J., and Pla A. Purification and characterization of paraoxon hydrolase from rat liver. Biochem. J. 321 (1997) 595-601
36. Rodrigo L., Gil F., Hernández A.F., and Pla A. Identification of two rat liver proteins with paraoxonase activity: biochemical evidence for the identity of paraoxonase and arylesterase. Chem.-Biol. Interact. 119-120 (1999) 263-275
37. Ozols J. Isolation and complete covalent structure of liver microsomal paraoxonase. Biochem. J. 338 (1999) 265-272
38. Rodrigo L., Gil F., Hernández A.F., Lopez O., and Pla A. Identification of paraoxonase 3 in rat liver microsomes: purification and biochemical properties. Biochem. J. 376 (2003) 261-268
39. Pla A., Rodrigo L., Hernández A.F., Gil F., and Lopez O. Effect of metal ions and calcium on purified PON1 and PON3 from rat liver. Chem.-Biol. Interact. 167 (2007) 63-70
40. Gaidukov L., Rosenblat M., Aviram M., and Tawfik D.S. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, stimulation of lipo-lactonase, and macrophage cholesterol efflux. J. Lipid Res. 47 (2006) 2492-2502
41. Rochu D., Cléry-Barraud C., Renault F., Chevalier A., Bon C., and Masson P. Capillary electrophoresis versus differential scanning calorimetry for the analysis of free enzyme versus enzyme-ligand complexes: in the search of the ligand-free status of cholinesterases. Electrophoresis 27 (2006) 442-451
42. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Meged R., Dvir H., Ravelli R.B.G., McCarthy A., Toker L., Silman I., Sussman J., and Tawfik D.S. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11 (2004) 412-419